# US biotech opportunities amid China's rise

**Created:** 12/20/2025 21:11:11  
**Updated:** 12/20/2025 21:12:29  
**Exported:** 12/20/2025 21:36:25  
**Link:** [https://claude.ai/chat/35e545db-b738-4ba4-8820-489e3c224806](https://claude.ai/chat/35e545db-b738-4ba4-8820-489e3c224806)  

## Response:
12/20/2025, 9:12:29 PM

````plaintext
Thought process: Synthesized China biotech trends to identify US startup opportunities.

The user is a healthcare VC interested in understanding the opportunities that the rise of China's biotech sector creates for US-based startups and market dynamics. They want to think through startup ideas and market dynamics, with a focus on practical "so what" implications.

Let me search for recent information on China biotech trends and US competitive dynamics to give them current, actionable insights.
````

I'll search for the latest on China biotech dynamics and US competitive responses to give you current market context.

````plaintext
Web Search: China biotech 2025 US competition biosecurity regulations
````

> **Geopolitics and Strategic Competition Behind U.S.-China Genomic Data Policies - Law and Biosciences Blog - Stanford Law School** [stanford.edu](https://law.stanford.edu/2025/09/01/geopolitics-and-strategic-competition-behind-u-s-china-genomic-data-policies/)
>
> **TESTIMONY USCC June 5, 2025** [uscc.gov](https://www.uscc.gov/sites/default/files/2025-06/Jeroen_Groenewegen-Lau_Testimony.pdf)
>
> **China’s WuXi AppTec, after evading threat of U.S. restrictions, comes out ahead** [statnews.com](https://www.statnews.com/2025/11/17/wuxi-apptec-dodges-sanctions-sales-soar/)
>
> **Biopharmaceuticals Rising: China’s Strategic Pivot to Southeast Asia Amid Great Power Tech Competition | Carnegie Endowment for International Peace** [carnegieendowment.org](https://carnegieendowment.org/research/2025/01/biopharmaceuticals-rising-chinas-strategic-pivot-to-southeast-asia-amid-great-power-tech-competition?lang=en)
>
> **Senate passes crackdown on Chinese biotech** [axios.com](https://www.axios.com/2025/10/10/china-biotech-ban-senate-national-security)
>
> **Senate backs China competition amendment in defense bill** [fiercepharma.com](https://www.fiercepharma.com/pharma/senate-endorses-biosecure-act-successor-time-adopting-softer-tone-and-omitting-wuxi)
>
> **BIOSECURE Act Advances in the US Senate | Insights | Greenberg Traurig LLP** [gtlaw.com](https://www.gtlaw.com/en/insights/2025/11/biosecure-act-advances-in-the-us-senate)
>
> **National Security Commission on Emerging Biotechnology: Final Report and Options for Congress | Congress.gov | Library of Congress** [congress.gov](https://www.congress.gov/crs-product/IN12546)
>
> **Biotech Battle: US Legislators Go On the Offensive - CEPA** [cepa.org](https://cepa.org/article/biotech-battle-us-legislators-go-on-the-offensive/)
>
> **Executive Summary - Biotech** [senate.gov](https://www.biotech.senate.gov/final-report/chapters/executive-summary/)
>
````plaintext
Thought process

This is great context on the regulatory and competitive landscape. Now let me search for more specific information on US biomanufacturing opportunities and FDA regulatory modernization.
````

````plaintext
Web Search: US biomanufacturing reshoring CDMO capacity 2025 investment
````

> **The Great Reshoring: How $24.86 Billion Reshaped CDMO Manufacturing in 2025 - PharmaSource** [pharmasource.global](https://pharmasource.global/content/news/cdmo-news/the-great-reshoring-how-24-86-billion-reshaped-cdmo-manufacturing-in-2025/)
>
> **KPMG. Make the Difference. The Biologics Manufacturing Rivalries:** [kpmg.com](https://assets.kpmg.com/content/dam/kpmgsites/ch/pdf/the-biologics-manufacturing-wars.pdf.coredownload.inline.pdf)
>
> **CPHI Experts Report that Small to Mid-sized US CDMOs Must Invest Now to Benefit from 2025 Contract Funding Surge | Pharmaceutical Technology** [pharmtech.com](https://www.pharmtech.com/view/cphi-experts-report-that-small-to-mid-sized-us-cdmos-must-invest-now-to-benefit-from-2025-contract-funding-surge)
>
> **US Captures 97% of $7.2B CDMO Investment Surge in September - PharmaSource** [pharmasource.global](https://pharmasource.global/content/us-captures-97-of-7-2b-cdmo-investment-surge-in-september/)
>
> **Big Pharma & US Manufacturing Investment - DCAT Value Chain Insights** [dcatvci.org](https://www.dcatvci.org/features/big-pharma-us-manufacturing-investment/)
>
> **US sees 185% jump in tenant demand for biomanufacturing space, as lab leasing craters | Pharma Manufacturing** [pharmamanufacturing.com](https://www.pharmamanufacturing.com/all-articles/article/55296385/us-sees-185-jump-in-tenant-demand-for-biomanufacturing-space-as-lab-leasing-craters)
>
> **What economic or market trends are having the biggest impact on CDMO capacity and pipelines in 2025, and what will 2026 bring?** [pharmasalmanac.com](https://www.pharmasalmanac.com/articles/what-economic-or-market-trends-are-having-the-biggest-impact-on-cdmo-capacity-and-pipelines-in-2025-and-what-will-2026-bring)
>
> **Biomanufacturing Trend Analysis: Capacity Expansion, M&A Activity, And Regional Footprint Landscape** [grandviewresearch.com](https://www.grandviewresearch.com/market-trends/biomanufacturing-capacity-expansion-regional-footprint-landscape-trend-analysis)
>
> **AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS| Amgen** [amgen.com](https://www.amgen.com/newsroom/press-releases/2025/09/amgen-announces-650m-expansion-of-us-manufacturing-creating-hundreds-of-new-jobs)
>
> **The Case for Reshoring Manufacturing to the United States | Pharmaceutical Commerce** [pharmaceuticalcommerce.com](https://www.pharmaceuticalcommerce.com/view/reshoring-manufacturing-united-states)
>
````plaintext
Thought process

This is excellent - there's a massive reshoring wave with $24.86 billion invested in CDMO capacity in 2025, with 74% going to the US. Let me search for more specific information on FDA regulatory modernization and China clinical trials.
````

````plaintext
Web Search: FDA accelerated approval Phase 1 trial reforms 2025
````

> **Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies - McGuireWoods** [mcguirewoods.com](https://www.mcguirewoods.com/client-resources/alerts/2025/1/rethinking-fdas-accelerated-approval-pathway-new-draft-guidances-and-implications-for-drug-companies/)
>
> **Accelerated Approval confirmatory trials requirement may further complicate life science deals | White & Case LLP** [whitecase.com](https://www.whitecase.com/insight-alert/accelerated-approval-confirmatory-trials-requirement-may-further-complicate-life)
>
> **Accelerated Approval Program | FDA** [fda.gov](https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program)
>
> **FDA Issues New Draft Guidance on Getting Confirmatory Trials “Underway” for Accelerated Approvals | Advisories | Arnold & Porter** [arnoldporter.com](https://www.arnoldporter.com/en/perspectives/advisories/2025/01/fda-guidance-confirmatory-trials-for-accelerated-approval)
>
> **FDA’s Recent Guidance on Accelerated Approval and Implications for Rare Diseases** [morganlewis.com](https://www.morganlewis.com/blogs/asprescribed/2025/02/fdas-recent-guidance-on-accelerated-approval-and-implications-for-rare-diseases)
>
> **FDA Issues Draft Guidance on Accelerated Approval: A Substantial Evidentiary and Procedural Overhaul to this High-Profile Pathway** [thefdalawblog.com](https://www.thefdalawblog.com/2025/01/fdas-issues-draft-guidance-on-accelerated-approval-a-substantial-evidentiary-and-procedural-overhaul-to-this-high-profile-pathway/)
>
> **New FDA Guidance: Accelerated Approval Accountability – Inside ProEd** [proedcomblog.com](https://proedcomblog.com/2025/02/04/new-fda-guidance-accelerated-approval-accountability/)
>
> **FDA Issues Draft Guidance Describing When a Confirmatory Trial of a Drug Seeking Accelerated Approval Is “Underway” | Insights | Ropes & Gray LLP** [ropesgray.com](https://www.ropesgray.com/en/insights/alerts/2025/01/fda-issues-draft-guidance-describing-when-a-confirmatory-trial-of-a-drug-seeking)
>
> **Accelerated approval: Navigating FDA’s recent guidance and confirmatory trial considerations :: Parexel** [parexel.com](https://www.parexel.com/insights/blog/accelerated-approval-navigating-fdas-recent-guidance-and-confirmatory-trial-considerations)
>
> **Federal Register :: Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway; Draft Guidance for Industry; Availability** [federalregister.gov](https://www.federalregister.gov/documents/2025/01/07/2024-31527/accelerated-approval-and-considerations-for-determining-whether-a-confirmatory-trial-is-underway)
>
````plaintext
Thought process

Let me search for more specific information on China biotech licensing deals and cross-border clinical trial opportunities.
````

````plaintext
Web Search: China biotech licensing deals 2025 US partnerships cross-border
````

> **Drugs from China are reshaping biotech. Track the licensing deals here. | BioPharma Dive** [biopharmadive.com](https://www.biopharmadive.com/news/china-biotech-drug-licensing-deals-pipeline/758283/)
>
> **China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus** [biopharmaapac.com](https://biopharmaapac.com/report/60/6738/chinas-biopharma-dealmaking-surges-in-h1-2025-driven-by-record-licensing-and-oncology-focus.html)
>
> **Key Trends and Considerations in Cross-Border Life Sciences Partnering-Licensing and NewCo Transactions Between Chinese and US/European Companies // Cooley // Global Law Firm** [cooley.com](https://www.cooley.com/news/insight/2025/2025-08-01-key-trends-and-considerations-in-cross-border-life-sciences-partnering-licensing)
>
> **China’s biotech industry is on the rise. Will it reshape US pharma?** [acs.org](https://cen.acs.org/pharmaceuticals/drug-development/Chinas-biotech-industry-rise-reshape/103/web/2025/09)
>
> **China’s Biopharma Boom in Global Drug Licensing Deals | EC Innovations** [ecinnovations.com](https://www.ecinnovations.com/blog/chinas-biopharma-boom-in-global-drug-licensing-deals/)
>
> **China Innovative Pharma Going Global - ARC Group** [arc-group.com](https://arc-group.com/china-innovative-pharma/)
>
> **NewCo licensing models are tipping deals in favour of China’s biotechs - Pharmaceutical Technology** [pharmaceutical-technology.com](https://www.pharmaceutical-technology.com/features/newco-licensing-models-are-tipping-deals-in-favour-of-chinas-biotechs/)
>
> **Inside Biotech: China’s Licensing Boom Collides with US Pullback** [discoveryalert.com.au](https://discoveryalert.com.au/chinas-biotech-licensing-boom-us-pullback-2025/)
>
> **Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion | South China Morning Post** [scmp.com](https://www.scmp.com/business/china-business/article/3336609/chinese-biotech-scizengs-global-licensing-deal-yield-us144-billion)
>
> **China Biotech Boom: Generics Producer to Innovation Leader | Morgan Stanley** [morganstanley.com](https://www.morganstanley.com/insights/articles/china-biotech-boom-generics-to-innovators)
>
````plaintext
Thought process: Synthesized biotech market data into startup opportunities framework.

This is excellent data. Now let me synthesize this into a comprehensive framework for the VC. I have great information on:
1. BIOSECURE Act and regulatory dynamics
2. US reshoring of biomanufacturing ($24.86B in 2025, 74% to US)
3. China biotech licensing boom (32% of global value in H1 2025)
4. NewCo structures and cross-border deal evolution
5. FDA regulatory changes (not major Phase 1 reforms but accelerated approval changes)

Let me create a structured response with clear startup opportunities and market dynamics.
````

This is a rich space with significant asymmetries and tailwinds. Let me break this down into market dynamics, then map to concrete startup opportunities with the "so what" for each.

---

## Current State: The Geopolitical Arbitrage Window

**The core dynamic:** China's share of global biotech licensing value soared to about 32% of worldwide out-licensing deal value in Q1 2025, up from 21% in 2023–24. Meanwhile, total disclosed CDMO investment reached $24.86 billion in 2025, with 74% of all capital flowing to the United States—a dramatic geographic concentration.

This isn't decoupling—it's bifurcation with interdependence. WuXi AppTec's U.S. revenues climbed 31.9% to about $3.1 billion in the first nine months of 2025—even while facing regulatory pressure. The industry isn't ready to fully decouple, but is actively de-risking.

---

## Market Dynamics to Watch

### 1. The "NewCo" Structure Explosion
A NewCo deal differs from a traditional license insofar as rights to an asset are not granted directly from a biotech to an established pharma developer. Instead, a NewCo is set up outside China where it receives rights to develop and commercialize the candidate.

**So what:** This creates opportunities for US-domiciled vehicles that can hold China-originated IP cleanly. Regulatory arbitrage in corporate structuring is now a core competency, not a back-office function.

### 2. The Cost-Quality Spread Is Closing
Chinese innovative assets often command smaller upfront payments (around 60–70% lower) and more modest total deal sizes (40–50% less) compared to Western peers. Yet among the 24 license-out deals exceeding US$1 billion in H1 2025: 42% involved antibody-based drugs, 33% involved ADCs.

**So what:** China isn't producing discount molecules—they're producing frontier modalities (ADCs, bispecifics) at lower cost. This is deflationary for US biotech valuations unless differentiated.

### 3. The Talent Bottleneck Is Real
The limiting factor may not be infrastructure but talent—operating complex, highly regulated plants requires skilled workers, and the U.S. talent pool is already stretched.

**So what:** This creates massive opportunity in workforce development, AI-assisted manufacturing operations, and potentially immigration policy advocacy as a competitive lever.

---

## Startup Opportunities Matrix

| **Theme** | **Opportunity** | **Why Now** | **So What / Thesis** |
|-----------|-----------------|-------------|----------------------|
| **Biomanufacturing Reshoring** | US-focused CDMO for biologics/cell therapy | 185% spike in demand for biomanufacturing space over the past six months + $270B in pharma commitments | The capex is flowing; need startups capturing modular/flexible capacity serving emerging biotechs priced out of tier-1 CDMOs |
| **Supply Chain Intelligence** | Real-time supplier mapping/compliance for BIOSECURE | Supply-chain due diligence—conduct a structured review of all vendors providing biotechnology-related equipment or services, tracing through to second-tier subcontractors | Every pharma company now needs "country of origin" visibility across their supply chain; analogous to post-GDPR privacy tooling boom |
| **Cross-Border Deal Infrastructure** | NewCo formation-as-a-service platform | Chinese biotech companies typically have complex corporate structures involving Cayman, Hong Kong and PRC entities, often with limited intercompany agreements governing IP | Standardize the corporate/legal scaffolding for US-China licensing deals; transactional volume is there, friction is high |
| **Clinical Trial Orchestration** | Multi-geography trial management (US + China + SEA) | Focus on US-based enrollment, as trials relying solely on foreign recruitment may face increased scrutiny by the FDA | FDA wants US enrollment but pharma wants China speed/cost; need platforms that orchestrate this elegantly with regulatory compliance |
| **API/Intermediate Reshoring** | Domestic small molecule synthesis | Three of the future US sites announced will focus on manufacturing APIs, reshoring capabilities of small-molecule chemical synthesis | Lilly and others building API capacity domestically; opportunity for contract synthesis partners or continuous manufacturing tech |
| **Workforce Enablement** | Bioprocessing training + workforce-as-a-service | CDMOs that can pair resilient networks with proactive workforce development will be best positioned to thrive | Think "Springboard for biotech" or staffing platforms with embedded training for GMP manufacturing |
| **Southeast Asia Bridging** | Singapore/Thailand manufacturing JVs | By establishing manufacturing operations in Singapore, Chinese firms can leverage the city-state's robust regulatory environment | "Friend-shoring" hub that satisfies both US regulatory preference and China's need for non-US market access |
| **Genomic Data Sovereignty** | Federated analysis platforms for cross-border trials | A new DOJ rule prohibits and restricts certain data transactions involving the transfer or access to bulk human genomic data by countries of concern | The data can't move, but the compute and algorithms can; federated learning infrastructure becomes essential |

---

## Regulatory Angle: What's Actually Moving

The FDA story is less about "faster Phase 1" and more about **confirmatory trial discipline**. FDA's second guidance in January 2025 clarified its definition of "underway" for confirmatory trials, generally requiring trials to be actively enrolling patients prior to approval.

**So what:** This actually *tightens* accelerated approval, creating more pressure for well-designed trials upfront. Advantage goes to:
- CROs that can orchestrate global enrollment efficiently
- Platforms that help sponsors design confirmatory trials earlier (End-of-Phase 2 alignment with FDA)
- Companies with US patient access infrastructure

---

## The Contrarian Angle

Most VCs will pile into "reshoring CDMOs." The less obvious plays:

1. **Bridge infrastructure, not walls.** The $480 billion in M&A and business development capacity sitting at US/EU pharma needs to flow somewhere. Build the pipes (legal, operational, regulatory) that make China-to-US licensing seamless and compliant.

2. **Southeast Asia is the real winner.** Chinese biopharmaceutical companies see Southeast Asia as an attractive location to re-establish supply chains due to the region's proximity to China and its extensive regional networks. Singapore, Thailand, and Indonesia biotech infrastructure is under-invested relative to the capital seeking "friend-shore" exposure.

3. **Talent is the binding constraint.** All the capital in the world can't build a plant without GMP-trained operators. Thermo Fisher's $2 billion U.S. investment needs bodies to run it. Workforce development at scale is infrastructure.

---

## What Would Make Me Cautious

- **Policy whiplash:** "In four years, we'll have another administration, and maybe this goes the entire opposite direction." Long-dated reshoring capex faces administration risk.
- **China self-sufficiency:** If China succeeds in replacing Illumina (already restricted), the bifurcation becomes permanent and the licensing window closes.
- **Biosimilar price pressure:** China's volume-based-procurement template could compress margins on legacy US blockbuster treatments 30%.

---

Want me to go deeper on any of these verticals—specific company examples, market sizing, or regulatory nuances?





---
Powered by [Claude Exporter](https://www.claudexporter.com)